Achieving asthma control in practice: Understanding the reasons for poor control
John Haughney(University of Aberdeen), Leif Bjermer(Lund University), Alan Kaplan(TD Bank Group), Henry Chrystyn(21c Consultancy (United Kingdom)), David Price(Optimum Therapeutics (United States)), Alf Tunsäter(Lund University), Jennifer Versnel(Summit (United Kingdom)), Nick May, Mandy Moffat(University of Aberdeen), Eamonn Shanahan(Farran Technology (Ireland)), Rob Horne(University College London), Elizabeth V. Hillyer
Cited by 230
Related Papers
Canadian Thoracic Society Recommendations for Management of Chronic Obstructive Pulmonary Disease – 2007 Update
|Canadian Respiratory Journal|2007|685
Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study
|The Lancet Respiratory Medicine|2015|584
MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
|Journal of Allergy and Clinical Immunology|2010|578
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels
|CHEST Journal|2016|426
EUFOREA consensus on biologics for CRSwNP with or without asthma
|Allergy|2019|378